Functional domains within fusion proteins: Prospectives for development of peptide inhibitors of viral cell fusion

Bioscience Reports

Volumn 20, Issue 6, 2000, Pages 535-555

  Shai, Y ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Antiviral peptides; Fluorescence; Membrane fusion; Peptide lipid interaction; Viral fusion inhibitors

Indexed keywords

ANTIVIRUS AGENT; PROTEIN INHIBITOR; VIRUS FUSION PROTEIN;

ANTIVIRAL ACTIVITY; CELL FUSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PARAMYXOVIRUS; PROTEIN CONFORMATION; RECEPTOR BINDING; SHORT SURVEY; VIRUS CELL INTERACTION; VIRUS ENVELOPE;

ANTIVIRAL AGENTS; LIPID BILAYERS; MEMBRANE FUSION; PROTEIN STRUCTURE, TERTIARY; VIRAL FUSION PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS; PARAMYXOVIRIDAE;

EID: 0034442295     PISSN: 01448463     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010411021326     Document Type: Short Survey

References (145)

1. Structural basis for paramyxovirus-mediated membrane fusion
2. Membrane-induced step in the activation of Sendai virus fusion protein
3. Membrane fusion mediated by coiled coils: A hypothesis
4. Oligomerization of the hydrophobic heptad repeat of gp41
5. All-D-magainin: Chirality, antimicrobiaI activity and proteolytic resistance
6. A trimeric subdomain of the Simian Immunodeficiency Virus enveloped glycoprotein
7. Influence of chirality on the structure of phospholipid monolayers
8. Identification of the fusion peptide of primate immunodeficiency viruses
9. Oblique membrane insertion of viral fusion peptide probed by neutron diffraction
10. Differentiation of lipid-associating helices by use of three-dimensional molecular hydrophobicity potential calculations
11. Orientation into the lipid bilayer of an asymmetric amphipathic helical peptide located at the N-terminus of viral fusion proteins
12. A leucine zipper structure present in the measles virus fusion protein is not required for its tetramerization but is essential for fusion
13. Structure of influenza hemagglutinin at the pH of membrane fusion
14. Interaction of influenza virus hemagglutinin with a lipid monolayer. A comparison of the surface activities of intact virions, isolated hemagglutinins, and a synthetic fusion peptide
15. A spring-loaded mechanism for the conformational change of influenza hemagglutinin
16. Sequence analysis of gene encoding the fusion glycoprotein of pneumonia virus of mice suggests possible conserved secondary structure elements in paramyxovirus fusion glycoproteins
17. Core structure of gp41 from the HIV envelope glycoprotein
18. HIV entry and its inhibition
19. The amino-terminal fusion domain peptide of human immunodeficiency virus type 1 gp41 inserts into the sodium dodecyl sulfate micelle primarily as a helix with a conserved glycine in the micelle-water interface
20. Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein
21. Lipids in biological membrane fusion
22. An early stage of membrane fusion mediated by the low pH conformation of influenza hemagglutinin depends upon membrane lipids
23. Interaction of influenza hemagglutinin amino-terminal peptide with phospholipid vesicles: A fluorescence study
24. Structural study of the interaction between the SIV fusion peptide and model membranes
25. Synthesis and properties of an all-D model ribonuclease S-peptide
26. Mutational analysis of the fusion peptide of the human immunodeficiency virus type 1: Identification of critical glycine residues
27. A study of carbobenzoxy-D-phenylalanine-phenylalanine-glycine, an inhibitor of membrane fusion, in phospholipid bilayers with multinuclear magnetic resonance
28. Cell biology of virus entry
29. Folding and assembly of viraI membrane proteins
30. Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity
31. What studies of fusion peptides tell us about viral envelope glycoprotein-mediated membrane fusion
32. Paramyxovirus fusion protein: Characterization of the core trimer, a rod-shaped complex with helices in anti-parallel orientation
33. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein
34. Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket
35. A trans-dominant mutation in human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp41 inhibits membrane fusion when expressed in target cells
36. Membrane orientation of the SIV fusion peptide determines its effect on bilayer stability and ability to promote membrane fusion
37. Lipid polymorphism and protein-lipid interactions
38. Structural requirements for the inhibition of membrane fusion by carbobenzoxy-D-Phe-Phe-Gly
39. Retrovirus envelope domain at 1.7 angstrom resolution
40. A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity
41. Capture of an early fusion-active confirmation of HIV-1 gp41
42. Detection of a fusion peptide sequence in the transmembrane protein of human imunodeficiency virus
43. A general model for the transmembrane proteins of HIV and other retroviruses
44. A leucine zipper motif in the ectodomain of Sendai virus fusion protein assembles in solutions and in membranes and specifically binds biologically-active peptides and the virus
45. Structure-function study of a heptad repeat positioned near the transmembrane domain of Sendai virus fusion protein which blocks virus-cell fusion
46. A peptide derived from a conserved domain of Sendai virus fusion protein inhibits virus-cell fusion. A plausible mode of action
47. Direct evidence that the N-terminal heptad repeat of Sendai virus fusion protein participates in membrane fusion
48. Sendai virus internal fusion peptide: Structure and functional characterization and a plausible mode of viral entry inhibition
49. Effect of the N-terminal glycine on the secondary structure, orientation and interaction of the influenza hemagglutinin fusion peptide with lipid bilayers
50. Analyzing the fusion process of influenza hemagglutinin by mutagenesis and molecular modeling
51. Interaction of mutant influenza virus hemagglutinin fusion peptides with lipid bilayers: Probing the role of hydrophobic residue size in the central region of the fusion peptide
52. Differential adhesion of cells to enantiomorphous crystal surfaces
53. Hydrophobic binding of the ectodomain of influenza hemagglutinin to membranes occurs through the "fusion peptide"
54. Androctonin, a hydrophilic disulphide-bridged non-haemolytic anti-microbial peptide: A plausible mode of action
55. Entry mechanism of enveloped viruses. Implications for fusion of intracellular membranes
56. Trypsin action on the growth of sendai virus in tissue culture cells
57. Studies on the fusion peptide of a paramyxovirus fusion glycoprotein: Roles of conserved residues in cell fusion
58. Activation of the Sendai virus fusion protein (f) involves a conformational change with exposure of a new hydrophobic region
59. Structural characterization of viral fusion proteins
60. An amino acid in the heptad repeat 1 domain is important for the haemagglutin-neurominidase-independent fusing activity of simian virus 5 fusion protein
61. HIV-1 inhibition by a peptide
62. Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors
63. A core trimer of the paramyxovirus fusion protein: Parallels to influenza virus hemagglutinin and HIV-1 gp41
64. Peptide inhibitors of enveloped virus infection inhibit phospholipid vesicle fusion and Sendai virus fusion with phospholipid vesicles
65. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
66. Fusion peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes and inhibit cell-cell fusion. Structure-function study
67. Membrane-induced conformational change during the activation of HIV-1 gp41
68. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation
69. Mode of action of an antiviral peptide from HIV-1: Inhibition at a post lipid-mixing stage
70. Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins
71. A mechanism of protein-mediated fusion: Coupling between refolding of the influenza hemagglutinin and lipid rearrangements
72. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion
73. Membrane binding and conformational properties of peptides representing the NH2 terminus of influenza HA-2
74. Specificity and promiscuity in membrane helix interactions
75. Glycophorin A dimerization is driven by specific interactions between transmembrane alpha-helices
76. A trimeric structural domain of the HIV-1 transmembrane glycoprotein
77. Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: Conserved helical interactions underlie the broad inhibitory activity of gp41 peptides
78. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9 Å resolution
79. Fusogenic activity of SIV (simian immunodeficiency virus) peptides located in the GP32 NH2 terminal domain
80. Correlation between fusogenicity of synthetic modified peptides corresponding to the NH2-terminal extremity of simian immunodeficiency virus gp32 and their mode of insertion into the lipid bilayer: An infrared spectroscopy study
81. Lipid membrane fusion induced by the human immunodeficiency virus type 1 gp41 N-terminal extremity is determined by its orientation in the lipid bilayer
82. D-enantiomers of 15-residue cecropin A-melittin hybrids
83. Total chemical synthesis of a D-enzyme: The enantiomers of HIV-1 protease show reciprocal chiral substrate specificity
84. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41
85. Interaction of the HIV-1 fusion peptide with phospholipid vesicles: Different structural requirements for fusion and leakage
86. Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human imunodeficiency virus-induced syncytium formation
87. Detection of influenza hemagglutinin interaction with biological membranes by photosensitized activation of [125I]iodonaphthylazide
88. Peptides and membrane fusion: Towards an understanding of the moelcular mechanism of protein-induced fusion
89. The polar region consecutive to the HIV fusion peptide participates in membrane fusion
90. Paramyxovirus F1 protein has two fusion peptides: Implications for the mechanism of membrane fusion
91. Liposome destabilization induced by the HIV-1 fusion peptide effect of a single amino acid substitution
92. Membrane fusion induced by the HIV type 1 fusion peptide: Modulation by factors affecting glycoprotein 41 activity and potential anti-HIV compounds
93. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1
94. A synthetic all D-amino acid peptide corresponding to the N-terminal sequence of HIV-1 gp41 recognizes the wild-type fusion peptide in the membrane and inhibits HIV-1 envelope glycoprotein-mediated cell fusion
95. Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes
96. A peptide from the heptad repeat of human immunodeficiency virus gp41 shows both membrane binding and coiled-coil formation
97. A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendia virus-cell fusion: An emerging similarity with functional domains of other viruses
98. Interaction of fluorescently labeled analogues of the amino-terminal fusion peptide of Sendai virus with phospholipid membranes
99. Mutational analysis of the leucine zipper motif in the Newcastle disease virus fusion protein
100. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution
101. Specific inhibition of paramyxovirus and myxovirus replication by oligopeptides with amino acid sequences similar to those at the N-termini of the F1 or HA2 viral polypeptides
102. Studies on the structure of the influenza virus hemagglutinin at the pH of membrane fusion
103. Phosphatidylinositol-dependent membrane fusion induced by a putative fusogenic sequence of Ebola virus
104. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Envmediated fusion and virus infectivity
105. Studies with crosslinking reagents on the oligomeric structure of the Env glycoprotein of HIV
106. Two disulfide-linked polypeptide chains constitute the active F protein of paramyxoviruses
107. A single amino acid change in the Newcastle disease virus fusion protein alters the requirements for HN protein in fusion
108. Molecular recognition between membrane-spanning polypeptides
109. A leucine zipper stabilizes the pentameric membrane domain of phospholamban and forms coiled-core pore structure
110. Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion
111. Coiled coils in both intracellular vesicle and viral membrane fusion
112. Inhibition of human immunodeficiency virus type 1 (HIV-1) penetration into target cells by synthetic peptides mimicking the N-terminus of the HIV-1 transmembrane glycoprotein
113. Interaction of human immunodeficiency virus (HIV-1) fusion peptides with artificial lipid membranes
114. Membrane fusion-inhibiting peptides do not inhibit influenza virus fusion or the Ca(2+)-induced fusion of negatively charged vesicles
115. Influenza hemagglutinin-mediated membrane fusion: Influence of receptor binding on the lag phase preceding fusion
116. Protein-mediated membrane fusion
117. Influenza hemagglutinin assumes a tilted conformation during membrane fusion as determined by attenuated total reflection FTIR spectroscopy
118. 2-terminal segment during influenza virus-induced membrane fusion
119. Discrete regions of HIV-1 gp41 defined by syncytia-inhibiting affinity purified human antibodies
120. Membrane proteins: From sequence to structure
121. Fusogenic segments of bovine leukemia virus and simian immunodeficiency virus are interchangeable and mediate fusion by means of oblique insertion in the lipid bilayer of their target cells
122. All D-amino acid-containing channel-forming antibiotic peptides
123. Oligomeric organization of gp120 on infections human immunodeficiency virus type 1 particles
124. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain
125. Structural basis for membrane fusion by enveloped viruses
126. Atomic structure of the ectodomain from HIV-1 gp41
127. The ectodomain of HIV-1 Env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminus fusion peptide
128. Membrane fusion by peptide analogues of influenza virus hemagglutinin
129. Temperature dependence of fusion by Sendai virus
130. Viral and cellular membrane fusion proteins
131. Membrane fusion
132. Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex
133. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion
134. The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure
135. A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition
136. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection
137. The crystal structure of the SIV gp41 ectodomain at 1.47 A resolution
138. Effects of the "fusion peptide" from measles virus on the structure of N-methyl dioleoylphosphatidylethanolamine membranes and their fusion with Sendai virus
139. On the mechanism of inhibition of viral and vesicle membrane fusion by carbobenzoxy-D-phenylalanyl-L-phenylalanylglycine
140. Analysis of a peptide inhibitor of paramyxovirus (NDV) fusion using biological assays, NMR, and molecular modeling
141. Interaction of peptides with sequences from the Newcastle disease virus fusion protein heptad repeat regions
142. Insertion of a coiled-coil peptide from influenza virus hemagglutinin into membranes
143. A lipid/protein complex hypothesis for exocytotic fusion pore formation